Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | AGER | Q15109 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362394 | 0.96 | TDP1 (0.47) | TDP1L3MBTL1TNK2BTKCYP1A2 | |
| SCHEMBL1360093 | 0.91 | CYP1A2 (0.42) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1360001 | 0.90 | CYP1A2 (0.41) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1361648 | 0.87 | GRM5 (0.40) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1361758 | 0.87 | ICMT (0.42) | TDP1L3MBTL1TNK2CYP1A2CYP3A4 | |
| SCHEMBL4820642 | 0.87 | CYP1A2 (0.39) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1361314 | 0.87 | CYP3A4 (0.39) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4815192 | 0.86 | CYP1A2 (0.39) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL961476 | 0.86 | POLB (0.42) | TDP1L3MBTL1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1361075 | 0.86 | CYP1A2 (0.39) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067453-B2 | Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-7396848-B1 | oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | BDNF, NGF, NTRK2 | TDP1 3338/4885L3MBTL1 4541/4885TNK2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.